Entrada Therapeutics (TRDA) Cash & Equivalents (2020 - 2026)

Entrada Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $76.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 12.69% year-over-year to $76.4 million; the TTM figure through Mar 2026 stood at $76.4 million (up 12.69% YoY), while the FY2025 annual figure was $90.4 million, down 10.69% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $76.4 million, down from $90.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $227.6 million in Q1 2023, with the low at $45.2 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $78.0 million (2024), against an average of $90.2 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 84.49% in 2022, then surged 168.96% in 2023.
• Entrada Therapeutics' Cash & Equivalents stood at $45.2 million in 2022, then jumped by 49.7% to $67.6 million in 2023, then jumped by 49.72% to $101.2 million in 2024, then fell by 10.69% to $90.4 million in 2025, then declined by 15.43% to $76.4 million in 2026.
• Business Quant data shows TRDA's Cash & Equivalents at $76.4 million in Q1 2026, $90.4 million in Q4 2025, and $93.3 million in Q3 2025.